Physician profile
Mary Lake Polan
NPI 1336164623
$862,345.05
in general payments reported to CMS, 2019-2025
3 companies · $177K in 2025
The $177K reported for 2025 was more than what 99% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,102 · 2020: $183K · 2021: $181K · 2022: $839 · 2024: $315K · 2025: $177K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $474K · Travel and Lodging: $18K · Food and Beverage: $700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $473,570.52 |
| Travel and Lodging | $17,979.14 |
| Food and Beverage | $700.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho-Clinical Diagnostics, INC. | $492,249.66 | 2024-2025 | |
| Quidel Corporation | $317,460.34 | 2019-2022 | |
| Pfizer INC. | $52,635.05 | 2021 |
Research and ownership
$1,083,423.04 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Polan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.